Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence

Jeffrey Jensen, William Schlaff, Keith Gordon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. Design: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. Setting: Not applicable. Patient(s): Women with endometriosis diagnosed by validated means. Intervention(s): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. Main Outcome Measure(s): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). Result(s): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. Conclusion(s): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.

Original languageEnglish (US)
Pages (from-to)137-152.e1
JournalFertility and Sterility
Volume110
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Endometriosis
Contraceptive Agents
Dyspareunia
Pain
Dysmenorrhea
Pelvic Pain
Progestins
Contraceptives, Oral, Hormonal
Therapeutics
Placebos
Pharmaceutical Databases
Gonadotropin-Releasing Hormone
MEDLINE
Observational Studies
Randomized Controlled Trials
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • contraceptives
  • Endometriosis
  • estrogen
  • pain
  • progestin

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Use of combined hormonal contraceptives for the treatment of endometriosis-related pain : a systematic review of the evidence. / Jensen, Jeffrey; Schlaff, William; Gordon, Keith.

In: Fertility and Sterility, Vol. 110, No. 1, 01.07.2018, p. 137-152.e1.

Research output: Contribution to journalArticle

@article{5dd1f3e856b740abbb2e378c7b692790,
title = "Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence",
abstract = "Objective: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. Design: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. Setting: Not applicable. Patient(s): Women with endometriosis diagnosed by validated means. Intervention(s): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. Main Outcome Measure(s): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). Result(s): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. Conclusion(s): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.",
keywords = "contraceptives, Endometriosis, estrogen, pain, progestin",
author = "Jeffrey Jensen and William Schlaff and Keith Gordon",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.fertnstert.2018.03.012",
language = "English (US)",
volume = "110",
pages = "137--152.e1",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Use of combined hormonal contraceptives for the treatment of endometriosis-related pain

T2 - a systematic review of the evidence

AU - Jensen, Jeffrey

AU - Schlaff, William

AU - Gordon, Keith

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. Design: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. Setting: Not applicable. Patient(s): Women with endometriosis diagnosed by validated means. Intervention(s): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. Main Outcome Measure(s): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). Result(s): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. Conclusion(s): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.

AB - Objective: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. Design: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. Setting: Not applicable. Patient(s): Women with endometriosis diagnosed by validated means. Intervention(s): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. Main Outcome Measure(s): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). Result(s): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. Conclusion(s): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.

KW - contraceptives

KW - Endometriosis

KW - estrogen

KW - pain

KW - progestin

UR - http://www.scopus.com/inward/record.url?scp=85048714431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048714431&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2018.03.012

DO - 10.1016/j.fertnstert.2018.03.012

M3 - Article

C2 - 29937152

AN - SCOPUS:85048714431

VL - 110

SP - 137-152.e1

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -